Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
125
Market Cap
0.00M

Momentum Score

…

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. The company was founded in 1991 and is based in Minneapolis, Minnesota.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
12.00M
Revenue Per Share
0.56
Gross Profit TTM
5.66M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
-288.95%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Type yearly yearly yearly yearly yearly
Date 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Income before tax -7.62M -4.28M -4.64M -3.73M -
Net income -7.61M -4.29M -4.70M -3.73M -
Selling general administrative 8.15M 10.23M 9.97M 7.90M 10.44M
Gross profit 5.90M 8.35M 8.38M 6.54M 8.97M
Ebit -3.97M -4.26M -3.87M -3.62M -
Operating income -3.97M -4.26M -3.87M -3.62M -
Other operating expenses 0.10M 0.10M 0.09M - -
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Non recurring 3.04M 0.16M 0.16M - -
Income tax expense -0.02M 0.01M 0.06M 0.01M -
Total revenue 14.01M 16.48M 17.03M 12.57M 14.77M
Total operating expenses 17.98M 20.74M 20.89M 16.19M -
Cost of revenue 8.12M 8.13M 8.64M 6.03M 5.80M
Total other income expense net -3.65M -0.02M -0.77M -0.10M -
Net income from continuing ops -7.61M -4.29M -4.70M -3.73M -
Net income applicable to common shares -7.61M -4.29M -4.70M -3.73M -
Breakdown 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Type yearly yearly yearly yearly yearly
Date 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Total assets 5.67M 12.53M 12.68M 6.76M 10.20M
Intangible assets 1.37M 1.59M 2.26M 0.10M 0.12M
Other current assets 0.06M 0.13M 0.29M 0.25M 0.14M
Total liab 12.64M 12.11M 12.05M 1.92M 2.00M
Total stockholder equity -6.98M 0.42M 0.63M 4.85M 8.21M
Deferred long term liab 3.73M 4.06M 4.65M - -
Other current liab 1.34M 0.69M 2.40M 0.02M 1.56M
Common stock 0.21M 0.21M 0.15M 0.14M 0.14M
Retained earnings -126.63M -119.02M -114.73M -110.03M -
Other liab 3.77M 4.14M 4.76M 0.16M -
Good will - 3.04M 3.12M - -
Other assets 0.15M 1.05M 0.67M 0.01M 0.35M
Cash 0.72M 2.29M 1.90M 3.06M 5.70M
Total current liabilities 4.29M 2.64M 7.29M 1.76M 2.00M
Short term debt 0.75M 5.33M - - -
Short long term debt 0.75M 5.33M - - -
Property plant equipment 0.47M 0.73M 0.86M 0.86M 1.01M
Total current assets 3.68M 6.12M 5.77M 5.79M -
Net tangible assets -8.35M -4.20M -4.75M 4.74M -
Net receivables 1.50M 2.13M 2.13M 1.36M -
Long term debt 4.59M 5.33M - - -
Inventory 1.40M 1.57M 1.45M 1.13M 1.50M
Accounts payable 0.89M 0.63M 3.38M 0.74M 0.43M
Breakdown 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Type yearly yearly yearly yearly yearly
Date 2014-06-30 2013-06-30 2012-06-30 2011-06-30 2010-06-30
Change to liabilities 0.26M 1.76M 2.63M 0.31M -
Total cashflows from investing activities -0.04M -1.48M -0.56M -0.28M -
Total cash from financing activities - 3.83M 0.12M 0.00M 0.01M
Change to operating activities 0.01M -0.07M 0.41M -0.15M -
Net income -7.61M -4.29M -4.70M -3.73M -
Change in cash -1.57M 0.39M -1.16M -2.64M -
Total cash from operating activities -1.53M -1.96M -0.71M -2.37M -
Depreciation 0.59M 0.67M 0.69M 0.56M -
Other cashflows from investing activities -0.01M -1.40M -0.51M - -
Change to inventory 0.27M -0.63M 0.13M 0.24M -
Change to account receivables 0.62M 0.02M -0.74M 0.07M 0.08M
Sale purchase of stock - 3.83M 0.12M 0.00M -
Change to netincome 4.33M 0.57M 0.85M 0.34M -
Capital expenditures 0.03M 0.08M 0.06M 0.27M 0.08M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ULGX
Urologix Inc
-
-%
0.00 - - 0.00 - 0.40 -9.52
ABT
Abbott Laboratories
1.11
1.07%
104.98 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
1.40
1.39%
102.00 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
3.24
1.03%
316.32 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Urologix Inc

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. The company was founded in 1991 and is based in Minneapolis, Minnesota.

14405 21st Avenue North, Minneapolis, MN, United States, 55447

763 475 1400

61

Name Title Year Born
Bryon Merade Chairman & CEO NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…